Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.

Central European Institute of Technology Brno University of Technology Purkynova 656 123 612 00 Brno Czech Republic

Department of Biochemistry Faculty of Science Charles University Albertov 2030 128 40 Prague 2 Czech Republic

Department of Chemistry and Biochemistry Mendel University in Brno Zemedelska 1 613 00 Brno Czech Republic

Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 Prague 5 CZ 15006 Czech Republic

Zobrazit více v PubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2018;68:394–424. PubMed

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:1–48. PubMed PMC

Jiao QL, Bi L, Ren YD, Song SL, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17:12. PubMed PMC

Yin YL, Yuan X, Gao HL, Yang Q. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. Int J Pharm. 2020;573:17. PubMed

Tridente G. Kinases. In: Tridente G, editor. Adverse Events and Oncotargeted Kinase Inhibitors: Academic Press. 2017. p: 9-56.

Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57. PubMed

Segaliny AI, Tellez-Gabriel M, Heymann M-F, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015;4:1–12. PubMed PMC

Knape MJ, Ballez M, Burghardt NC, Zimmermann B, Bertinetti D, Kornev AP. et al. Divalent metal ions control activity and inhibition of protein kinases. Metallomics. 2017;9:1576–84. PubMed

Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol. 2001;311:1011–26. PubMed

Mayer BJ. Perspective: Dynamics of receptor tyrosine kinase signaling complexes. FEBS Lett. 2012;586:2575–9. PubMed PMC

Gelens L, Saurin AT. Exploring the function of dynamic phosphorylation-dephosphorylation cycles. Dev Cell. 2018;44:659–63. PubMed

Heldin C-H. Protein tyrosine kinase receptor signaling overview. In: Bradshaw RA, Dennis EA, editors. Handbook of Cell Signaling (Second Edition). San Diego: Academic Press. 2010. p: 419-26.

Tridente G. Kinase Inhibitors. In: Tridente G, editor. Adverse Events and Oncotargeted Kinase Inhibitors: Academic Press. 2017. p: 57-80.

Fleuren EDG, Zhang L, Wu J, Daly RJ. The kinome 'at large' in cancer. Nat Rev Cancer. 2016;16:83–98. PubMed

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34. PubMed PMC

Lahiry P, Torkamani A, Schork NJ, Hegele RtA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet. 2010;11:60–74. PubMed

Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127–33. PubMed PMC

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE. et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693–704. PubMed PMC

Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 2013;28:9–18. PubMed

Huang C-W, Tsai H-L, Chen Y-T, Huang C-M, Ma C-J, Lu C-Y. et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer. 2013;13:1–12. PubMed PMC

Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 2016;7:74362–79. PubMed PMC

McLendon R, Friedman A, Bigner D. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8. PubMed PMC

Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016;22:259–67. PubMed

Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22. PubMed PMC

Xie N, Tian C, Wu H, Yang X, liu L, Li J. et al. FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. Ther Adv Med Oncol. 2020;12:1–15. PubMed PMC

Li Y-L, Zhao H, Ren X-B. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med. 2016;13:206–14. PubMed PMC

Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharm Res. 2018;136:97–107. PubMed

Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM. et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res. 2016;22:2993–3004. PubMed PMC

Lisi L, Ciotti GMP, Chiavari M, Ruffini F, Lacal PM, Graziani G. et al. Vascular endothelial growth factor receptor 1 in glioblastoma-associated microglia/macrophages. Oncol Rep. 2020;43:2083–92. PubMed

Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806:108–21. PubMed PMC

Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M. et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013;123:1732–40. PubMed PMC

Paulsson J, Ehnman M, Östman A. PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 2014;10:1695–708. PubMed

Kiwerska K, Wroblewska J, Kaluzna A, Marszalek A. Justification of direct Sanger sequencing application for detection of KIT and PDGFR gene mutations in formalin-fixed, paraffin-embedded samples from gastrointestinal stromal tumours. J Clin Pathol. 2020;73:1–7. PubMed

Nordby Y, Richardsen E, Rakaee M, Ness N, Donnem T, Patel HRH. et al. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. Sci Rep. 2017;7:1–9. PubMed PMC

Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619–30. PubMed PMC

Hunter HA, Koc H, Koc EC. c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer. Cell Signal. 2020;72:1–11. PubMed PMC

Djeungoue-Petga M-A, Lurette O, Jean S, Hamel-Cote G, Martín-Jimenez R, Bou M. et al. Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells. Cell Death Dis. 2019;10:1–15. PubMed PMC

Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J. et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50. PubMed PMC

Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF. et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. PubMed PMC

Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:1–9. PubMed PMC

Bellinger AM, Arteaga CL, Force T. et al. Cardio-oncology. Circulation. 2015;132:2248–58. PubMed PMC

Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353. PubMed

Wu P, Clausen MH, Nielsen TE. Allosteric small-molecule kinase inhibitors. Pharmacol Therapeut. 2015;156:59–68. PubMed

Dar AC, Shokat KM. The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling. Anu Rev Biochem. 2011;80:769–95. PubMed

Zuccotto F, Ardini E, Casale E, Angiolini M. Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation. J Med Chem. 2010;53:2681–94. PubMed

Gavrin LK, Saiah E. Approaches to discover non-ATP site kinase inhibitors. MedChemComm. 2013;4:41–51.

Lamba V, Ghosh I. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Current pharmaceutical design. 2012;18:2936–45. PubMed

Liao JJ. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. J Med Chem. 2007;50:409–24. PubMed

van Linden OPJ, Kooistra AJ, Leurs R, de Esch IJP, de Graaf C. KLIFS: A Knowledge-Based Structural Database To Navigate Kinase-Ligand Interaction Space. J Med Chem. 2014;57:249–77. PubMed

Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharm Res. 2016;103:26–48. PubMed

Carles F, Bourg S, Meyer C, Bonnet P. PKIDB: A curated, annotated and updated database of protein kinase inhibitors in clinical trials. Molecules. 2018;23:1–18. PubMed PMC

Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077–80. PubMed

Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20:2249–56. PubMed PMC

Eckstein N, Röper L, Haas B, Potthast H, Hermes U, Unkrig C. et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res. 2014;33:15. - PubMed PMC

Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene. 2015;34:3215–25. PubMed

Han HJ, Ekweremadu C, Patel N. Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer. J Drug Deliv Sci Tec. 2019;52:1051–60.

Jain K, Mehra NK, Jain NK. Potentials and emerging trends in nanopharmacology. Curr Opin Pharmacol. 2014;15:97–106. PubMed

Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3:703–17. PubMed PMC

Black KCL, Wang Y, Luehmann HP, Cai X, Xing W, Pang B. et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano. 2014;8:4385–94. PubMed PMC

Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? Pharm Res. 2008;26:1–9. PubMed

Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32:3435–46. PubMed PMC

Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015;88:20150207. - PubMed PMC

Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S. et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291–309. PubMed PMC

Kou L, Sun J, Zhai Y, He Z. The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian J Pharm Sci. 2013;8:1–10.

Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7:606–18. PubMed PMC

Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–51. PubMed PMC

Cao Y. The toxicity of nanoparticles to human endothelial cells. In: Saquib Q, Faisal M, Al-Khedhairy AA, Alatar AA, editors. Cellular and Molecular Toxicology of Nanoparticles. Cham: Springer International Publishing. 2018. p: 59-69.

Han W, Xie B, Li Y, Shi L, Wan J, Chen X. et al. Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. Theranostics. 2019;9:7458–73. PubMed PMC

Wan J, Qiao Y, Chen X, Wu J, Zhou L, Zhang J. et al. Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy. Adv Funct Mater. 2018;28:1–12.

Moradpour Z, Barghi L. Novel approaches for efficient delivery of tyrosine kinase inhibitors. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2019;22:37–48. PubMed

van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:315–26. PubMed

Puszkiel A, Noe G, Thomas-Schoemann A, Bellesoeur A, Boudou-Rouquette P, Vidal M. et al. Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. Int J Pharmacokinet. 2017;2:257–83.

Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. Eur J Pharm Sci. 2014;57:322–32. PubMed

Managuli RS, Raut SY, Reddy MS, Mutalik S. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Exp Opin Drug Deliv. 2018;15:787–804. PubMed

Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Rev. 2015;41:412–22. PubMed

Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U. et al. Clinical pharmacokinetics of tyrosine kinase inhibitors. Clin Pharm. 2011;50:551–603. PubMed

Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S. et al. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int J Pharm. 2017;534:1–13. PubMed

Qiu Q, Lu M, Li C, Luo X, Liu X, Hu L. et al. Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. AAPS PharmSciTech. 2018;19:3571–83. PubMed

Nazari-Vanani R, Azarpira N, Heli H, Karimian K, Sattarahmady N. A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. Colloids Surf B Biointerfaces. 2017;160:65–72. PubMed

Lu X, Liu S, Han M, Yang X, Sun K, Wang H. et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Int J Pharm. 2019;560:126–35. PubMed

Hoogenboezem EN, Duvall CL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018;130:73–89. PubMed PMC

Gao W, Jia X, Wu J, Song Y, Yin J, Zhang M. et al. Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy. J Drug Deliv Sci Tec. 2019;54:1–10.

Li Y, Yang B, Zhang X. Oral delivery of imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption. Int J Pharm. 2019;568:1–9. PubMed

Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10:7921–4. PubMed PMC

Tridente G. Adverse Events. In: Tridente G, editor. Adverse Events and Oncotargeted Kinase Inhibitors: Academic Press. 2017. p: 81-93.

Cryer AM, Chan C, Eftychidou A, Maksoudian C, Mahesh M, Tetley TD. et al. Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer. ACS Appl Mater Interfaces. 2019;11:16336–46. PubMed

Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G. et al. Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity. Int J Nanomedicine. 2015;10:3163–70. PubMed PMC

Wan X, Zheng X, Pang X, Zhang Z, Zhang Q. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer. Colloids Surf B Biointerfaces. 2015;136:817–27. PubMed

Wan X, Zheng X, Pang X, Pang Z, Zhao J, Zhang Z. et al. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016;7:34038–51. PubMed PMC

Abshire C, Murad HY, Arora JS, Liu J, Mandava SH, John VT. et al. Focused Ultrasound-Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma. J Pharm Sci. 2017;106:1355–62. PubMed

Song Z, Lin Y, Zhang X, Feng C, Lu Y, Gao Y. et al. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects. Int J Nanomedicine. 2017;12:1941–58. PubMed PMC

Heffron TP. Small molecule kinase inhibitors for the treatment of brain cancer. J Med Chem. 2016;59:10030–66. PubMed

Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W. et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13:674–81. PubMed

Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:320941. PubMed PMC

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Update. 2015;19:1–12. PubMed

Han W, Shi L, Ren L, Zhou L, Li T, Qiao Y. et al. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduct Target Ther. 2018;3:1–10. PubMed PMC

Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47. PubMed

Lockman PR, Koziara JM, Mumper RlJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target. 2004;12:635–41. PubMed

Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian J Pharm Sci. 2019;14:480–96. PubMed PMC

Lakkadwala S, dos Santos Rodrigues B, Sun C, Singh J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J Control Release. 2019;307:247–60. PubMed PMC

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M. et al. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016;61:94–101. PubMed

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B. et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018;132:307–20. PubMed PMC

Park SE, Kim DE, Kim MJ, Lee JS, Rho JK, Jeong S-Y. et al. Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation. Oncol Rep. 2019;41:525–33. PubMed

Chen S, Liang Q, Liu E, Yu Z, Sun L, Ye J. et al. Curcumin/sunitinib co-loaded BSA-stabilized SPIOs for synergistic combination therapy for breast cancer. J Mater Chem B. 2017;5:4060–72. PubMed

Li F, Mei H, Gao Y, Xie X, Nie H, Li T. et al. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017;145:56–71. PubMed

Zhao L, Yang G, Shi Y, Su C, Chang J. Co-delivery of gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. J Nanobiotechnol. 2015;13:57. PubMed PMC

Joo LJS, Weiss J, Gill AJ, Clifton-Bligh R, Brahmbhatt H, MacDiarmid JA. et al. RET kinase-regulated microRNA-153-3p improves therapeutic efficacy in medullary thyroid carcinoma. Thyroid. 2019;29:830–44. PubMed

Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol. 2011;2:80–93. PubMed PMC

Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10:130–7. PubMed PMC

Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S. A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. Int J Nanomedicine. 2016;11:179–200. PubMed PMC

Greish K, Jasim A, Parayath N, Abdelghany S, Alkhateeb A, Taurin S. et al. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. J Drug Target. 2018;26:692–708. PubMed

Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V. et al. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience. 2017;11:1–35. PubMed PMC

Zhao L, Yang G, Shi Y, Su C, Chang J. Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. Journal of Nanobiotechnology. 2015;13:57. PubMed PMC

Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Acta Biomater. 2018;76:257–74. PubMed

Hu H, Lin Z, He B, Dai W, Wang X, Wang J. et al. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. J Control Release. 2015;220:189–200. PubMed

Lu X, Liu S, Han M, Yang X, Sun K, Wang H. et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. International Journal of Pharmaceutics. 2019;560:126–35. PubMed

Srikar R, Suresh D, Zambre A, Taylor K, Chapman S, Leevy M. et al. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown. Sci Rep. 2016;6:1–14. PubMed PMC

Tan H-Y, Wang N, Lam W, Guo W, Feng Y, Cheng Y-C. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer. 2018;17:1–15. PubMed PMC

Huo M, Zhao Y, Satterlee AB, Wang YS, Xu Y, Huang L. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release. 2017;245:81–94. PubMed PMC

Kim H, Khanna V, Kucaba TA, Zhang W, Ferguson DM, Griffith TS. et al. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Mol Pharm. 2019;16:1200–10. PubMed

Yin W, Yu X, Kang X, Zhao Y, Zhao P, Jin H. et al. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. Small. 2018;14:1802372. PubMed

Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials. 2017;143:1–16. PubMed

Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Kanwal S, Ali B. et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. Biomed Pharmacother. 2018;108:752–6. PubMed

Naizhi W, Tao F, Xiaona L, Qin L. Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway. Acta Pharm. 2020;70:399–409. PubMed

Li W, Sun L, Lei J, Wu Z, Ma Q, Wang Z. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor-stromal crosstalk under hypoxic conditions via the IL-6/ERK/NF-κB axis. Oncol Rep. 2020;44:382–92. PubMed

Almutairi FM, El Rabey HA, Tayel AA, Alalawy AI, Al-Duais MA, Sakran MI. et al. Augmented anticancer activity of curcumin loaded fungal chitosan nanoparticles. Int J Biol Macromolecules. 2020;155:861–7. PubMed

de Freitas CF, Kimura E, Rubira AF, Muniz EC. Curcumin and silver nanoparticles carried out from polysaccharide-based hydrogels improved the photodynamic properties of curcumin through metal-enhanced singlet oxygen effect. Mater Sci Eng C. 2020;112:1–14. PubMed

Mansourizadeh F, Alberti D, Bitonto V, Tripepi M, Sepehri H, Khoee S. et al. Efficient synergistic combination effect of Quercetin with Curcumin on breast cancer cell apoptosis through their loading into Apo ferritin cavity. Colloids Surf B Biointerfaces. 2020;191:1–9. PubMed

Nosrati H, Danafar H, Rezaeejam H, Gholipour N, Rahimi-Nasrabadi M. Evaluation radioprotective effect of curcumin conjugated albumin nanoparticles. Bioorg Chem. 2020;100:1–7. PubMed

Dong Y, Yang Y, Wei Y, Gao Y, Jiang W, Wang G. et al. Facile synthetic nano-curcumin encapsulated Bio-fabricated nanoparticles induces ROS-mediated apoptosis and migration blocking of human lung cancer cells. Process Biochem. 2020;95:91–8.

Chen F-P, Liu L-L, Tang C-H. Spray-drying microencapsulation of curcumin nanocomplexes with soy protein isolate: Encapsulation, water dispersion, bioaccessibility and bioactivities of curcumin. Food Hydrocoll. 2020;105:105821.

Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y. et al. Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma. Mol Pharm. 2015;12:922–31. PubMed

Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83–92. PubMed PMC

Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A. et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci. 2012;103:1946–54. PubMed PMC

Kalash RS, Lakshmanan VK, Cho C-S, Park I-K. Theranostics. In: Ebara M, editor. Biomaterials Nanoarchitectonics: William Andrew Publishing. 2016. p: 197-215.

Muthu MS, Leong DT, Mei L, Feng S-S. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4:660–77. PubMed PMC

Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65:500–16. PubMed PMC

Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052–63. PubMed PMC

Cheng R, Meng F, Deng C, Klok H-A, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials. 2013;34:3647–57. PubMed

Noh GT, Kim M, Suh J-Y, Song Y, Lee CK, Baek JH. et al. Sunitinib-CLIO conjugate: A VEGFR/PDGFR-targeting active MR probe. Mol Imaging Biol. 2014;16:340–9. PubMed

Liu Y, Feng L, Liu T, Zhang L, Yao Y, Yu D. et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6:3231–42. PubMed

Hsu F-T, Liu H-S, Ali AAA, Tsai PH, Kao Y-C, Lu C-F. et al. Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system. Nanomed-Nanotechnol. 2018;14:1019–31. PubMed

Zhang Y, Zhang L, Lin X, Ke L, Li B, Xu L. et al. Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy. Chem Eng. 2019;372:483–95.

Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F. et al. BHQ-Cyanine-Based “Off-On” Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device. ACS Apl Mater Interfaces. 2019;11:42873–84. PubMed

Eckstein N, Roper L, Haas B, Potthast H, Hermes U, Unkrig C. et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res. 2014;33:10. PubMed PMC

Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4:1–16. PubMed PMC

Wu L-P, Wang D, Li Z. Grand challenges in nanomedicine. Mater Sci Eng C. 2020;106:1–7. PubMed

Barenholz YC. Doxil® - The first FDA-approved nano-drug: From an idea to a product. Handbook of Harnessing Biomaterials in Nanomedicine. 2012. p: 335-98.

Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J. et al. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine. Adv Mater. 2020;32:1–15. PubMed PMC

Shamay Y, Shah J, Isık M, Mizrachi A, Leibold J, Tschaharganeh DF. et al. Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater. 2018;17:361–8. PubMed PMC

Tropsha A, Mills KC, Hickey AJ. Reproducibility, sharing and progress in nanomaterial databases. Nat Nanotechnol. 2017;12:1111–4. PubMed PMC

Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: An Advanced Generative Adversarial Autoencoder Model for de novo Generation of New Molecules with Desired Molecular Properties in Silico. Mol Pharm. 2017;14:3098–104. PubMed

Bello T, Gujral TS. KInhibition: A Kinase Inhibitor Selection Portal. iScience. 2018;8:49–53. PubMed PMC

Lampa S, Alvarsson J, Arvidsson Mc Shane S, Berg A, Ahlberg E, Spjuth O. Predicting Off-Target Binding Profiles With Confidence Using Conformal Prediction. Frontiers in Pharmacology. 2018;9:1–13. PubMed PMC

Wang W, Sedykh A, Sun H, Zhao L, Russo DP, Zhou H. et al. Predicting Nano-Bio Interactions by Integrating Nanoparticle Libraries and Quantitative Nanostructure Activity Relationship Modeling. ACS Nano. 2017;11:12641–9. PubMed PMC

Vijay S, Gujral TS. Non-linear Deep Neural Network for Rapid and Accurate Prediction of Phenotypic Responses to Kinase Inhibitors. iScience. 2020;23:1–49. PubMed PMC

Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A. et al. An Ex vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017;77:3336–51. PubMed PMC

Xie Q, Faust K, Van Ommeren R, Sheikh A, Djuric U, Diamandis P. Deep learning for image analysis: Personalizing medicine closer to the point of care. Crit Rev Cl Lab Sci. 2019;56:61–73. PubMed

Min J, Im H, Allen M, McFarland PJ, Degani I, Yu H. et al. Computational Optics Enables Breast Cancer Profiling in Point-of-Care Settings. ACS Nano. 2018;12:9081–90. PubMed PMC

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF. et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP) Sci Transl Med. 2018;10:1–18. PubMed

Lim JJ, Goh J, Rashid MBMA, Chow EK-H. Maximizing Efficiency of Artificial Intelligence-Driven Drug Combination Optimization through Minimal Resolution Experimental Design. Adv Ther. 2020;3:1–7.

Blasiak A, Khong J, Kee T. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence. SLAS Technol. 2019;25:95–105. PubMed

Cova TFGG, Bento DlJ, Nunes SCC. Computational Approaches in Theranostics: Mining and Predicting Cancer Data. Pharmaceutics. 2019;11:1–28. PubMed PMC

Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X. et al. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol. 2020;38:497–518. PubMed PMC

Setten RL, Rossi JJ, Han S-P. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421–46. PubMed

Almurshedi AS, Radwan M, Omar S, Alaiya AA, Badran MM, Elsaghire H. et al. A novel pH-sensitive liposome to trigger delivery of afatinib to cancer cells: Impact on lung cancer therapy. J Mol Liq. 2018;259:154–66.

Coelho SC, Almeida GM, Pereira MC, Santos-Silva F, Coelho MAN. Functionalized gold nanoparticles improve afatinib delivery into cancer cells. Exp Opin Drug Deliv. 2016;13:133–41. PubMed

Xiao W, Ruan S, Yu W, Wang R, Hu C, Liu R. et al. Normalizing tumor vessels to increase the enzyme-induced retention and targeting of gold nanoparticle for breast cancer imaging and treatment. Mol Pharm. 2017;14:3489–98. PubMed

Kydd J, Jadia R, Rai P. Co-Administered Polymeric Nano-Antidotes for Improved Photo-Triggered Response in Glioblastoma. Pharmaceutics. 2018;10:1–18. PubMed PMC

Greish K, Jasim A, Parayath N, Abdelghany S, Alkhateeb A, Taurin S. et al. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. J Drug Target. 2018;26:692–708. PubMed

Dong C, Li B, Li Z, Shetty S, Fu J. Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity. Oncotarget. 2016;7:49699–709. PubMed PMC

Niza E, Noblejas-López MD, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J. et al. Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer. Nanomaterials. 2019;9:1–14. PubMed PMC

Niza E, Nieto-Jiménez C, Noblejas-López MD, Bravo I, Castro-Osma JA, de la Cruz-Martínez F. et al. Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy. Nanomaterials. 2019;9:1–14. PubMed PMC

Chauhan R, Balgemann R, Greb C, Nunn BM, Ueda S, Noma H. et al. Production of dasatinib encapsulated spray-dried poly (lactic-co-glycolic acid) particles. J Drug Deliv Sci Technol. 2019;53:1–8.

Adena SKR, Upadhyay M, Vardhan H, Mishra B. Gold nanoparticles for sustained antileukemia drug release: development, optimization and evaluation by quality-by-design approach. Nanomedicine. 2019;14:851–70. PubMed

Sabra SA, Sheweita SA, Haroun M, Ragab D, Eldemellawy MA, Xia Y. et al. Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells. J Pharm Sci. 2019;108:1713–25. PubMed

Kulkarni NS, Parvathaneni V, Shukla SK, Barasa L, Perron JC, Yoganathan S. et al. Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. Eur J Pharm Sci. 2019;133:145–59. PubMed

Kim DH, Choi YJ, Sung KJ, Yoo S-A, Sung YH, Kim JK. et al. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer. Mol Oncol. 2018;12:2182–90. PubMed PMC

Thakkar S, Sharma D, Misra M. Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: Assessment of In-vitro cytotoxicity. Eur J Pharm Sci. 2018;111:257–69. PubMed

Fathi M, Zangabad PS, Aghanejad A, Barar J, Erfan-Niya H, Omidi Y. Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib. Carbohydr Polym. 2017;172:130–41. PubMed

Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J. et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev Ind Pharm. 2017;43:1244–53. PubMed

Yang KM, Shin IC, Park JW, Kim K-S, Kim DK, Park K. et al. Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm. 2017;43:1557–65. PubMed

Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S. et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2016;137:339–49. PubMed

Kola Srinivas NS, Verma R, Pai Kulyadi G, Kumar L. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. Int J Nanomedicine. 2016;12:15–28. PubMed PMC

Kuruppu AI, Zhang L, Collins H, Turyanska L, Thomas NR, Bradshaw TD. An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib. Adv Healthc Mater. 2015;4:2816–21. PubMed

Lam ATN, Yoon J, Ganbold E-O, Singh DK, Kim DH, Cho K-H. et al. Colloidal gold nanoparticle conjugates of gefitinib. Colloids Surf B Biointerfaces. 2014;123:61–7. PubMed

Han W, Shi L, Ren L, Zhou L, Li T, Qiao Y. et al. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Tranduct Tar. 2018;3:1–16. PubMed PMC

Qiu Q, Li C, Song Y, Shi T, Luo X, Zhang H. et al. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta Biomater. 2019;92:184–95. PubMed

Kamali M, Dinarvand R, Maleki H, Arzani H, Mahdaviani P, Nekounam H. et al. Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma. RSC Adv. 2015;5:62214–9.

James AR, Unnikrishnan BS, Priya R, Joseph MM, Manojkumar TK, Raveendran PK. et al. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells. Tumor Biol. 2017;39:1010428317695946. PubMed

Cortese B, D'Amone S, Gigli G, Palama IE. Sustained anti-BCR-ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells. MedChemComm. 2015;6:212–21.

Buss JH, Begnini KR, Bruinsmann FA, Ceolin T, Sonego MS, Pohlmann AR. et al. Lapatinib-loaded nanocapsules enhances antitumoral effect in human bladder cancer cell. Front Oncol. 2019;9:203. - PubMed PMC

Lee SY, Cho H-J. Mitochondria targeting and destabilizing hyaluronic acid derivative-based nanoparticles for the delivery of lapatinib to triple-negative breast cancer. Biomacromolecules. 2019;20:835–45. PubMed

Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W. et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int J Pharm. 2015;484:16–28. PubMed

Kallus S, Englinger B, Senkiv J, Laemmerer A, Heffeter P, Berger W. et al. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomed-Nanotechnol. 2018;14:2632–43. PubMed PMC

Lang L, Shay C, Xiong Y, Thakkar P, Chemmalakuzhy R, Wang X. et al. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. J Hematol Oncol. 2018;11:1–13. PubMed PMC

Xu X, Tang X, Wu X, Feng X. Biosynthesis of sorafenib coated graphene nanosheets for the treatment of gastric cancer in patients in nursing care. J Photoch Photobio B. 2019;191:1–5. PubMed

Clavreul A, Roger E, Pourbaghi-Masouleh M, Lemaire L, Tetaud C, Menei P. Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug Deliv. 2018;25:1756–65. PubMed PMC

Liu J, Abshire C, Carry C, Sholl AB, Mandava SH, Datta A. et al. Nanotechnology combined therapy: tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in a murine model. BJU Int. 2017;119:342–8. PubMed

Callaghan C, Peralta D, Liu J, Mandava SH, Maddox M, Dash S. et al. Combined treatment of tyrosine kinase inhibitor-labeled gold nanorod encapsulated albumin with laser thermal ablation in a renal cell carcinoma model. J Pharm Sci. 2016;105:284–92. PubMed

Bianchini F, De Santis A, Portioli E, Russo Krauss I, Battistini L, Curti C. et al. Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools. Nanomed-Nanotechnol. 2019;18:135–45. PubMed

Alshahrani SM, Alshetaili AS, Alalaiwe A, Alsulays BB, Anwer MK, Al-Shdefat R. et al. Anticancer efficacy of self-nanoemulsifying drug delivery system of sunitinib malate. AAPS PharmSciTech. 2018;19:123–33. PubMed

Chen Y, Sun J, Huang Y, Lu B, Li S. Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. Mol Pharm. 2018;15:5162–73. PubMed PMC

Wang J, Wang H, Li J, Liu Z, Xie H, Wei X. et al. iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in vitro and in vivo Evaluation. ACS Appl Mater Interfaces. 2016;8:19228–37. PubMed

Sarkar S, Konar S, Prasad PN, Rajput S, Kumar BNP, Rao RR. et al. Micellear gold nanoparticles as delivery vehicles for dual tyrosine kinase inhibitor ZD6474 for metastatic breast cancer treatment. Langmuir. 2017;33:7649–59. PubMed

Wang D, Wu L-P. Nanomaterials for delivery of nucleic acid to the central nervous system (CNS) Mater Sci Eng C. 2017;70:1039–46. PubMed

Hsu F-T, Liu H-S, Ali AAA, Tsai P-H, Kao Y-C, Lu C-F. et al. Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system. Nanomed-Nanotechnol. 2018;14:1019–31. PubMed

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System